BENEFIT-RISK ANALYSIS OF ADALIMUMAB AND ALTERNATIVE TREATMENTS FOR MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS

被引：0
|
作者：
Hicks, K. A. [1 ]
Earnshaw, S. R. [1 ]
Shaw, J. W. [2 ]
Cifaldi, M. [2 ]
机构：
[1] RTI Hlth Solut, Res Triangle Pk, NC USA
[2] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.1360
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A439 / A440
页数：2
相关论文
共 50 条
  • [41] Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
    Sands, Bruce E.
    Peyrin-Biroulet, Laurent
    Loftus, Edward V., Jr.
    Danese, Silvio
    Colombel, Jean-Frederic
    Toruner, Murat
    Jonaitis, Laimas
    Abhyankar, Brihad
    Chen, Jingjing
    Rogers, Raquel
    Lirio, Richard A.
    Bornstein, Jeffrey D.
    Schreiber, Stefan
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (13): : 1215 - 1226
  • [42] Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis
    Tribich, Samuel
    Maurice, James
    FRONTLINE GASTROENTEROLOGY, 2020, 11 (02) : 173 - 173
  • [43] Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
    Biemans, Vince B. C.
    Hoentjen, Frank
    Pierik, Marieke J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (01): : 92 - 92
  • [44] Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China
    Tian, Lei
    Xiong, Xiaomo
    Guo, Qiang
    Chen, Yixi
    Wang, Luying
    Dong, Peng
    Ma, Aixia
    PHARMACOECONOMICS, 2020, 38 (12) : 1345 - 1358
  • [45] Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China
    Lei Tian
    Xiaomo Xiong
    Qiang Guo
    Yixi Chen
    Luying Wang
    Peng Dong
    Aixia Ma
    PharmacoEconomics, 2020, 38 : 1345 - 1358
  • [46] IMPACTS OF IMMEDIATE CHANGES IN DMARDS ON OUTCOMES IN RHEUMATOID ARTHRITIS WITH MODERATE-TO-SEVERE ACTIVITY
    Kim, D.
    Choi, C. -B.
    Sung, Y. -K.
    Cho, S. -K.
    Park, S. -Y.
    Choi, J. -Y.
    Yoo, D. -H.
    Lee, S. -S.
    Lee, J.
    Kim, J.
    Lee, H. -S.
    Kim, T. -H.
    Yoon, B. Y.
    Yoo, W. -H.
    Choe, J. -Y.
    Lee, S. -H.
    Shim, S. -C.
    Chung, W. T.
    Hong, S. -J.
    Lee, C. K.
    Koh, E.
    Jun, J. -B.
    Bang, S. -Y.
    Kim, S. -K.
    Cha, H. -S.
    Lee, J.
    Bae, S. -C.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 210 - 210
  • [47] Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: Comparison of adverse event-free response days in the CHAMPION trial
    Reich, Kristian
    Signorovitch, James
    Ramakrishnan, Karthik
    Yu, Andrew P.
    Wu, Eric Q.
    Gupta, Shiraz R.
    Bao, Yanjun
    Mulani, Parvez M.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 63 (06) : 1011 - 1018
  • [48] BUDGET IMPACT ANALYSIS OF CERTOLIZUMAB PEGOL IN THE MANAGEMENT OF PATIENTS WITH MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS IN GREECE
    Tzanetakos, C.
    Maniadakis, N.
    Kourlaba, G.
    Tzioufas, A.
    Goules, A.
    Theodoratou, T.
    Christou, P.
    VALUE IN HEALTH, 2014, 17 (07) : 375 - 375
  • [49] COST-EFFECTIVENESS OF RITUXIMAB VS ADALIMUMAB IN THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS
    Bynum, L. A.
    Joshi, N.
    VALUE IN HEALTH, 2010, 13 (03) : A126 - A126
  • [50] MICROARRAY PATHWAY ANALYSIS COMPARING BARICITINIB AND ADALIMUMAB IN MODERATE TO SEVERE RHEUMATOID ARTHRITIS FROM A PHASE 3 STUDY
    Emery, P.
    Taylor, P. C.
    Weinblatt, M. E.
    Tanaka, Y.
    Keystone, E. C.
    Dow, E. R.
    Higgs, R.
    Macias, W. L.
    Rocha, G.
    Rooney, T. P.
    Schlichting, D. E.
    Zuckerman, S. H.
    McInnes, I. B.
    Holzkaemper, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : A52 - A52
12345